EndoChoice® Launches Third Generation Fuse® Full Spectrum Endoscopy® System

ALPHARETTA, Ga.May 19, 2016 /PRNewswire/ — EndoChoice Holdings, Inc. (NYSE:  GI) announced today the full market release of its Generation 3 Full Spectrum Endoscopy® (Fuse®) system. Fuse Generation 3 includes an ergonomically advanced control body, incorporating over 50 system enhancements and a novel Adaptive Matrix Imaging technology called Lumos™, that enables physicians to see more with enhanced clarity. The company is beginning sales and distribution of Generation 3 scopes in the United States, European Union, and other select markets.

Lumos Adaptive Matrix Imaging takes a revolutionary approach to enhance the view of the mucosal structures and vascular patterns in their natural color and the ability for “always-on” functionality via smart enhancement technology, making it the first advanced imaging solution designed to improve the entire procedure.  Lumos is now launched in Europe with the CE mark, and is pending FDA clearance in the United States.

EndoChoice will highlight Fuse Generation 3 at Digestive Disease Week® (DDW®) in San Diego, California (Booth #4317), and at the SGNA™ 43rd Annual Course in Seattle, Washington.  EndoChoice will display at these meetings May 22 to 24.

Commenting on the new product release, Dr. Booker Dalton, Gastroenterologist at Digestive Healthcare of Georgia, said “Fuse Generation 3 is a significant advancement of the Full Spectrum Endoscopy system. Fuse’s new ergonomic design and system refinements greatly enhance the overall user experience. Coupled with its already impressive 330-degree field of view and published clinical value, Fuse is a game changer.”

Mark Gilreath, Founder and CEO of EndoChoice, stated, “We are truly excited to bring Fuse Generation 3 and Lumos to the world of GI. With Generation 3, not only do GI’s have an increased field of view to help detect lesions, they now have the ability to enhance anatomy like never before with Lumos Adaptive Matrix Imaging.  We believe these advancements take the Fuse platform to an unprecedented level in endoscopic screening.”